ALEXANDRIA, Va. -- The American Academy of PAs (AAPA) and CancerLinQ LLC announced today that they will be entering a partnership, with AAPA contributing expertise to the CancerLinQ® platform and potentially leveraging CancerLinQ Discovery™ for queries that will assist research efforts in the PA community aimed at improving the quality of patient care.

"By partnering with the AAPA, we are now bringing another facet of the cancer care team, the PAs, into our growing collaborative network," said CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick. "PAs will provide valuable thought leadership on how data analysis through CancerLinQ® can lead to improvements in care at the practice level. Having graduated from the Duke PA program, our formal collaboration with the AAPA is especially meaningful to me."

With more than 115,500 certified PAs across the country working in all medical and surgical specialties, they represent a vital component of health care teams, often leading these teams, as they work with physicians and other providers to deliver care. Because of their expertise in general medicine, they are on the front lines in monitoring and evaluating the quality of patient care and safety. By collaborating with CancerLinQ LLC, AAPA members will contribute their perspectives on improving the accuracy and completeness of CancerLinQ's data capture efforts in cancer centers and oncology practices across the U.S., where PAs assess patients for treatment effectiveness, manage side effects, and provide care coordination.
"AAPA is pleased to partner with CancerLinQ® to help advance important research that will ultimately improve patient care," said Josanne K. Pagel, MPAS, PA-C, president and board chair of AAPA. "PAs are on the forefront of using data in ways that enhance and improve healthcare, and on behalf of the profession we are pleased to be involved in this very important opportunity."

AAPA members will attend meetings of the CancerLinQ® Oncology Leadership Council and other CancerLinQ® advisory groups and will have access to CancerLinQ Discovery™ -- sub-cohorts of anonymized and statistically de-identified clinical data from the CancerLinQ® platform that physicians, researchers, and analysts in the oncology field can request from the CancerLinQ® Discovery Research & Publications Committee for use in creating new clinical knowledge and improving patient outcomes. The sets are pulled from the rapidly growing CancerLinQ® database, a real-world, big data initiative focused on cancer patient medical information.

Rad Oncology Homepage